The Promise and Challenges of Rare Cancer Treatments
Dr. William Smith, Pioneer Institute’s Visiting Fellow in Life Sciences, spoke about the challenges and opportunities for rare cancer treatments, and concerns about cost effectiveness tools such as the Quality Adjusted Life Year (QALY), in a video interview produced by Rare Cancers, a patient group based in Australia, for the November 26th Can Forum.
Watch the video below:
Get Updates On Our Life Sciences Work!
Related Content:
https://pioneerinstitute.org/wp-content/uploads/pharmacist-and-woman-1.jpg
1526
2290
Editorial Staff
https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png
Editorial Staff2019-04-23 00:00:112021-11-23 10:48:31Commentary: Proposed Drug Price Caps Would Stall Advances in Health Care
https://pioneerinstitute.org/wp-content/uploads/Female-doctor-talking-to-female-patient-1.jpg
1415
2122
Editorial Staff
https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png
Editorial Staff2019-04-18 00:00:302021-11-23 10:27:28HHS Secretary Alex Azar doesn’t want drug access to become an equation
https://pioneerinstitute.org/wp-content/uploads/birthday.jpeg
432
768
Editorial Staff
https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png
Editorial Staff2019-02-22 00:00:582021-12-29 12:14:00The U.S. shouldn’t use the ‘QALY’ in drug cost-effectiveness reviews
https://pioneerinstitute.org/wp-content/uploads/bottle-of-blue-pills-1.jpg
2304
3456
Editorial Staff
https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png
Editorial Staff2019-02-03 00:00:132021-12-29 12:12:04Baker’s Orwellian drug pricing policy
https://pioneerinstitute.org/wp-content/uploads/GavelSteth.jpg
468
800
Editorial Staff
https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png
Editorial Staff2019-01-24 06:00:002021-01-28 15:11:06Study Urges Caution Before Adopting ICER Reviews to Determine Cost Effectiveness of Treatments
